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As a precursor of the neurotoxic amyloid-b peptide, APP plays a central role in Alzheimer’s disease.
We have recently reported that the tumor suppressor p53 inhibits APP gene transcription through
the same DNA sequences that mediate an inhibitory effect of thyroid hormones. Now, we have ana-
lyzed whether the thyroid hormone T3 can modulate the effects of p53 on APP expression. Exposi-
tion to UVC radiation leads to a marked decrease of intracellular APP levels that is paradoxically
reversed by T3. Repression by UVC and reversion by the hormone are not observed in cells depleted
of p53, demonstrating a p53-dependent mechanism. These results suggest the existence of a cross-
talk between p53 and T3 that could play an important role in Alzheimer´s disease.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease is a neurodegenerative disorder of the hu-
man central nervous system that causes mental deterioration and
progressive dementia. The disease is characterized by a massive
loss of neurons that is accompanied by neuropathological lesions,
including the formation of senile plaques that are mainly com-
posed of b-amyloid protein, a hydrophobic peptide of 39- to 43-
residues amino acid [1,2]. The b-amyloid protein derives from a
set of alternatively spliced b-amyloid precursor proteins (APP),
which are encoded by a single gene located in human chromosome
21 [3]. APP plays a central role in Alzheimer’s disease, and it has
been suggested that an increase in the production of this protein
might actively contribute to the development of this pathology
[4,5], likely by inducing the synthesis and deposit of b-amyloid
[5,6], and the subsequent neurotoxicity [4]. In contrast, it has been
also reported that physiological APP levels may elicit neurotrophic
effects [7–9], and protect neuronal cells against the apoptosis in-
duced by insults such as ultraviolet radiation [10], or hypoglycemia
[8], thus preventing neurodegeneration. APP is ubiquitously ex-
pressed in mammalian tissues, and its expression has been proved
to be regulated by a variety of cellular mediators. In particular, we
have recently reported that p53, a transcription factor that is in-
creased in Alzheimer’s disease [11], may inhibit the expression of
APP in neuroblastoma cells [12]. Transient expression of p53, aschemical Societies. Published by Ewell as activation of this factor by camptothecin, a DNA damaging
agent, signiﬁcantly reduce the intracellular levels of APP, an effect
that appears to be mediated by sequences of the gene located
downstream of the transcriptional start site.
Of interest, we have previously described that thyroid hor-
mones decrease transcriptional activity of APP through sequences
located in the same region of the gene [13], and this coincidence
together with previous descriptions about physical and functional
interactions between p53 and the thyroid hormone receptor (TR)
[14,15] suggest that both transcription factors could cooperate to
regulate the APP gene expression. To check this hypothesis we
have now analyzed whether or not thyroid hormones may affect
the response of APP to p53 activated by UVC irradiation.2. Materials and methods
2.1. Chemicals
The A-8717 antibody, which recognizes the c-terminal region of
APP, the anti a-tubulin (#T6199) and DAPI were purchased from
Sigma. Antibodies against phospho-p53 and Caspase-3 antibody
were from cell signaling (cat. #9284 and 9661), and the antibody
against PARP as well as the goat anti-rabbit IgG-HRP were from
Santa-Cruz Biotechnology (cat. #2030). The pCMV-E6 expression
vector was kindly provided by Dr. S. Llanos (C.N.I.O., Spain) and
the siRNA against p53 was obtained from Dharmacon. An in situ
cell death detection kit from Roche was used for TUNEL labelling.lsevier B.V. All rights reserved.
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Murine N2a-b cells, a subclon of N2a that constitutively ex-
presses the b-isoform of the thyroid hormone receptor (TRb), were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum as previously described [16]. Pre-
vious to the experiments, the culture medium was replaced with a
similar medium containing serum depleted of thyroid hormone by
treatment with resin AG1X8 as described [17], and the cells were
then incubated in this medium for an additional 24-h period before
the beginning of experiments. For UV radiation, medium was re-
moved from the plates (p60) and the cells were exposed to differ-
ent ﬂuencies of UVC (254 nm) by using a Stratalinker 2400 UV
crosslinker from Stratagene (La Jolla, Ca, USA). Fresh medium
was then added and the cells were incubated by different time
periods before harvesting. At the indicated times, neurons were
collected for proteins determination, or ﬁxed and subjected to DAPI
staining and TUNEL labelling to estimate the UVC-induced cell
death. Cell death was estimated to be relative to the level of apop-
totic nuclei (TUNEL) in relationship to the total number of cells
(DAPI).
2.3. DNA transfection
For transient transfection of p53 siRNA or the E6 protein-coding
expression vector, the cells were plated on the previous day and
transfected with Lipofectamine 2000 following the instructions of
the manufacturer (Invitrogen, Carlsbad, CA). The transfected cells
were incubated for an additional period of 24 h, and then irradi-
ated and collected for immunoblotting determination 48 h later.
Each experiment was repeated at least 2–3 times with similar rel-
ative differences in regulated expression.
2.4. Western blot analysis
Cellular proteins were extracted by lysis with a buffer (150 mM
NaCl, 50 mM Tris pH 8, 2 mM EDTA, 1% Triton, 0.1% SDS) contain-
ing the protease inhibitors PMSF (1 mM) and leupeptin (10 lg/ml).
The protein content of cells was determined by using the BCA assay
(Pierce, IL), following the manufacturer’s instructions, and equal
amounts, 40 lg, of cell extracts were then electrophoresed in an
8% SDS–polyacrylamide gel, transferred to an immobilon polyvi-
nylidine diﬂuoride membrane. Non-speciﬁc binding was blocked
with 5% non-fat dried milk in TBS-T (Tris buffered saline, 0.1%
Tween 20) for 2–3 h at room temperature and the cellular APP
and levels of intracellular APP and phospho-p53 analyzed with
speciﬁc antibodies. After 1 h incubation at room temperature, the
membrane was washed and incubated with a second biotinylated
anti-rabbit antibody for one additional hour, washed again and ﬁ-
nally incubated for 1 h with 1:2000 peroxidase-conjugated strep-
tavidine. All incubations took place at room temperature, and
detection by enhanced chemiluminiscence (ECL, Amersham Inter-
national plc, England) was carried out according to the manufac-
turer’s indications. Dilutions of antibodies used against APP,
phospho-p53, and the loading control a-tubulin were, respectively,
1:4000, 1:1000 and 1:2000. Dilution of the second biotynilated
anti-rabbit antibody was 1:5000.
The apparent molecular mass (kDa) of the detected bands was
always determined by using a wide range protein standard (Mark
12 from Novex.-S, Diego, CA).
2.5. Statistical analysis
Unless indicated otherwise, all the data are the mean of two
independent experiments performed in duplicate. Signiﬁcance ofthe differences was calculated with the Student’s t-test and is indi-
cated in the ﬁgures with an asterisk (*P < 0.05).3. Results
3.1. UVC irradiation decreases cell content of APP in N2ab
neuroblastoma cells by a p53-dependent mechanism
We have previously demonstrated that exposition of cells to the
DNA damaging agent camptothecin leads to a signiﬁcant decrease
in the cellular content of APP, an effect that appears to be mediated
by the previous activation of p53 [12]. To further explore the effect
of p53 on APP, cells were exposed to different ﬂuencies of UVC irra-
diation by using a 254 nm emitting lamp, a source that is appropri-
ate to induce DNA damage, and therefore to activate the
endogenous p53. To verify and exclude doses of UVC that might re-
sults lethal to the cells, we ﬁrst analyzed the effects induced by a
wide range of UVC ﬂuences. Cells were irradiated with UVC doses
ranging from 20 to 600 J/m2, and the induced apoptosis and cell
viability were assessed 24 h after by immunodetection of apoptotic
markers such as activated caspase-3 or PARP or by using DAPI
staining and TUNEL labelling. As shown in Fig. 1, all the UV doses
used, in a dose-dependent manner caused apoptosis, as assessed
by the appearance of cleaved caspase-3 and the speciﬁc Mr
85 000 cleavage product of PARP. However, as shown in the lower
panel of the ﬁgure only exposition of cells to UV ﬂuencies higher
than 100 J/m2 was accompanied of a signiﬁcant increase in cell
death, as determined by the increasing percentage of TUNEL posi-
tive cells in relation with the total number of DAPI stained cells,
whereas the changes induced by doses of UV irradiation lower than
40 J/m2 only minimally affected the cell viability at the studied
time. Nevertheless, after 72–96 h, even doses of irradiation lower
than 100 J/m2 were effective in causing cell death (not illustrated).
To prove the effects of the UVC irradiation on p53 activation and
APP expression, cells were exposed to UVC ﬂuences between 10
and 40 J/m2, which as shown in Fig. 1, minimally affect cell
survival. Activated (phosphorylated) p53 and APP isoforms were
detected from cell lysates by Western blot using the speciﬁc anti-
bodies described under Experimental Procedures. Results are illus-
trated in panel A of Fig. 2. As expected, p53 was activated in all
irradiated cells, and this activation was evident even 48 h after
irradiation. In addition, the UVC irradiation caused a signiﬁcant de-
crease of APP levels, an effect that appeared to be dose-dependent
and that was more evident in those cells harvested 48 h after irra-
diation. Moreover, these results suggested a correlation between
p53 activation and APP decrease, and to further evaluate whether
UV-induced repression of APP is actually mediated by p53, we next
analyzed the effects of UV radiation in cells transiently transfected
with the human papillomavirus E6 gene, which encodes a small
protein that binds to and inactivates p53 [18]. Cells were irradiated
at 20 J/m2 and harvested 48 h after as described above. As shown in
panel B of the ﬁgure, transfection of pCMV-E6 abolished p53 acti-
vation and signiﬁcantly reversed the UV-induced repression of
APP, thus conﬁrming a p53-dependent mechanism.
3.2. Triiodothyronine reverses the UV-dependent reduction of APP
As shown in the previous ﬁgure, activation of endogenous p53
by UVC radiation leads to an evident reduction of intracellular
APP, an effect that as previously demonstrated could by exerted
at transcriptional level [12]. Because thyroid hormone T3 may also
inhibit the APP gene promoter activity through the same DNA se-
quences [13,19], we next analyzed whether T3 could affect the
APP response to UV. Cells were irradiated at 20 J/m2 UVC and incu-
bated for an additional period of 24 or 48 h in the presence or in
Fig. 1. Effects of the UVC irradiation on cell viability. N2ab cells were exposed to different doses of UVC light and further incubated for 24 h. Whole cells were then
photographed and collected for (A) Western blot detection of activated caspase-3, the 85 kDa cleaved fragment of PARP and a-tubulin as a loading control, or (B) cell death
analysis by ﬂuorescence microscopy after DAPI staining and TUNEL labelling.
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Fig. 2. UVC irradiation decreases intracellular content of APP. (A) Phospho-p53 (p-p53) and APP were determined in cell extracts obtained from N2ab cells irradiated with
UVC doses ranging between 10 and 40 J/m2 and incubated for the indicated time periods. (B) Analysis of phospho-p53 and APP levels in E6-expressing cells exposed to 20 J/m2
and incubated for 24 h. a-Tubulin was used as a loading control in both cases. A relative quantiﬁcation of those levels is also included at the right of the panel (*P < 0.05).
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protein extracted and the intracellular levels of activated p53 and
APP determined by Western blots. As illustrated in Fig. 3, the UV
irradiation caused a signiﬁcant activation (phosphorylation) of
the endogenous p53 that is followed by an evident reduction of
APP levels in all the irradiated cells. Of interest, the UVC-induced
reduction of APP was partially reversed by the thyroid hormone
T3, which would be then playing a signiﬁcant role in protecting
the cells against the effects induced by DNA damaging agents. In
addition, activation of p53 by UV was attenuated in T3-treated
cells, being this effect more apparent at 48 h.
In contrast with the results obtained in TR-expressing N2ab
cells, T3 was not able to affect the reduction of APP levels causedby p53 in parental N2a cells, which express very low receptor lev-
els, indicating that this is a thyroid hormone nuclear receptor-
dependent action. In addition, the thyroid hormone thyroxine
(T4) that binds nuclear TRs with low afﬁnity, but is more effective
than T3 on binding to a putative membrane receptor [20] that
mediates non-genomic actions of the hormone, was also uneffec-
tive (data not shown).
3.3. T3 reverses the UVC-induced repression of APP by a p53-
dependent mechanism
As shown in previous ﬁgures, the exposition of cells to UVC
irradiation leads to a signiﬁcant reduction of intracellular APP, an
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Fig. 3. Triiodothyronine reverses the UV-associated decrease of APP levels. Cells
were exposed to UVC irradiation (20 J/m2) and phospho-p53 (p-p53) and APP levels
were determined in lysates obtained from cells incubated for 24–48 h in the
presence or in the absence of 200 nM T3. A relative quantiﬁcation of the levels is
also included at the bottom of the ﬁgure.
2404 A. Cuesta et al. / FEBS Letters 583 (2009) 2401–2406effect that at least in part requires activation of p53, and that is
partially reversed by thyroid hormones. To further analyze
whether or not this protective effect of T3 is also mediated by a
p53-dependent mechanism we next analyzed the intracellular lev-
els of APP in cells depleted of p53 by E6 transient transfection or by
siRNA-mediated p53 knock-down. As shown in panel A of Fig. 4, T3
was effective in reversing the UV effects in control cells. However,
it was unable to reverse the residual decrease of APP induced by
UV in the E6-expressing cells. As an alternative approach, cells
were also depleted of p53 by RNA silencing. Cells grown to 70%
conﬂuence were irradiated after transfection with control or p53
speciﬁc siRNAs, incubated for 48 h in the presence or in the ab-
sence of 5nM T3 and then harvested for APP and phospho-p53
determination. The results obtained, illustrated in the panel B of
the ﬁgure, conﬁrm those obtained with the E6-expressing cells.
As expected, the UV irradiation caused p53 activation and de-
creased intracellular APP levels in cells transfected with the control
siRNA. Of interest, it should be noted that a dose of T3 that mini-
mally reduces the APP expression levels, was very effective in
reversing the UV-associated reduction of APP. In contrast, in the
p53 siRNA-transfected cells the inhibitory effect of the UV irradia-
tion on APP was strongly reduced even though only partial deple-
tion of p53 was achieved. In addition, the effect that T3 exerts on
the UV-induced repression of APP was essentially abolished in siR-
NA-transfected cells. These results strongly suggest that both, the
inhibitory effect of irradiation on APP as well as the protective
activity of T3, would be mediated by a p53-dependent mechanism.
3.4. T3-induced reversion of p53-dependent repression of APP is not
mediated at a transcriptional level
Since T3, as well as p53, have been described to decrease the
transcriptional activity of APP through DNA sequences located in
the same region (b.p. +55 to +102) of the promoter [12,13], we next
analyzed the existence of a possible crosstalk between p53 and the
thyroid hormone receptor (TR) on regulation of the APP promoter.
To prove whether or not the effect is actually mediated at a tran-
scriptional level, we analyzed APP promoter activity in transient
transfection experiments in the presence of p53 and T3. For this
purpose CAT activity was determined in N2a-b cells cotransfected
with reporter plasmids containing different fragments (1099/
+101, 307/+101, 15/+101 and +55/+101) of the APP gene and
an expression vector for p53 (or a control empty vector). Theresults obtained in cells incubated for 48 hours in the presence
and in the absence of T3 are illustrated in Fig. 5. As expected, pro-
moter activity was clearly reduced by p53 or T3, and the extent of
repression was very similar in both cases. However, in contrast
with that observed with APP protein levels, repression of APP pro-
moter by p53 was not reversed in cells exposed to both factors
simultaneously, thus suggesting that reversion of the UV-induced
repression of APP by T3 is not mediated at a transcriptional level.4. Discussion
The b-amyloid precursor protein plays a central role in Alzhei-
mer’s disease and its regulation appears to be essential since both,
increased as well as decreased levels of this protein could be con-
sidered as risk factors for this pathology. High levels of APP may
cause a higher production and deposit of b-amyloid, the principal
component of senile plaques, and low levels would be accompa-
nied by a signiﬁcant lost of the APP-dependent neurotrophic ef-
fects [8,21].
A number of factors have been described to regulate APP
expression. Among others, we have previously described that p53
[12], as well as the thyroid hormone T3 [19], can regulate APP gene
transcription, and inhibit the transcriptional activity of the APP
promoter. Of interest, expression of both thyroid hormones and
p53 transcription factor has been described to be altered in the
brain of Alzheimer patients [22,23].
Thyroid hormones control growth, development, and metabo-
lism in virtually all mammalian tissues. In particular, they play a
key role in the development and maintenance of basal forebrain
cholinergic neurons typically involved in Alzheimer’s disease
[24], and it has been reported that brain hypothyroidism may oc-
cur during the progress of this pathology [23]. Furthermore, we
have also demonstrated that thyroid hormone T3 may downregu-
late APP gene expression in neuroblastoma cells [19,25].
The tumor suppressor p53, which acts as a transcription factor
to regulate a variety of cellular functions including gene transcrip-
tion, DNA repair, cell cycle or cell death [26], has been reported to
be involved in many neurodegenerative diseases [27]. In Alzhei-
mer’s disease, p53 levels are increased in damaged neurons [11],
and an interesting correlation between the b-amyloid protein
and p53 has been reported. The b-amyloid protein may activate
p53 in selective neurons [28,29], and the precursor APP may pro-
tect neuronal cells against apoptosis by controlling p53 activation
[10].
p53 is constitutively expressed in most types of cells, including
neurons, and although is present at a low concentration in normal
cells, it can be upregulated and activated in response to a variety of
cellular stresses and DNA damage. In this work we have ﬁrst ana-
lyzed the APP expression in cells irradiated with different doses of
UVC (254 nm), which causes DNA damage and the subsequent acti-
vation of p53. As expected, activation (phosphorylation) of p53 was
signiﬁcantly increased in the irradiated cells, and we observed that
the intracellular content of APP was reduced in a dose-dependent
fashion by UV ﬂuences that minimally affect the cell viability at
the studied times. Moreover, the UV-induced reduction of APP
was clearly reversed in cells expressing the oncoprotein E6, a small
polypeptide that interacts with p53 [30] and promotes its rapid
degradation [31–33], thus suggesting that UV effects are mainly
mediated by a p53-dependent mechanism.
We have also analyzed whether or not the thyroid hormone T3
could modulate the inhibitory effect of UVC on APP levels. Surpris-
ingly, the inhibitory effect caused by the UV irradiation was con-
siderably reversed in cells incubated in the presence of T3, which
appears to protect the cells against the UV-induced damage. Re-
sults obtained in cells rendered deﬁcient in p53 by transient
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Fig. 4. p53 mediates the suppressive effect of thyroid hormone. Depletion of p53 abolishes the UV-dependent decrease of APP and the T3-induced reversion. (A) Intracellular
levels of APP and phospho-p53 (p-p53) were determined in wild type and E6-expressing N2ab cells exposed to UVC at a dose of 20 J/m2 and incubated for 48 h in the presence
or in the absence of 5 nM T3. Two graphs at the right illustrate the densitometric quantiﬁcation of the intracellular APP bands. Data are the average ± S.D. from two separate
experiments performed in duplicate, and are expressed relative to the total APP detected in non-irradiated cells. (B) APP and p-p53 levels were analyzed in cells transfected
with control (left) or p53 speciﬁc (right) siRNA after UVC irradiation and 48 h of incubation in the presence or in the absence of T3. A densitometric quantiﬁcation of data
obtained in two independent experiments performed in duplicate is shown at the bottom.
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Fig. 5. Regulation of the APP promoter activity by p53 and T3. CAT activity was determined in N2ab cells cotransfected with reporter plasmids that contain different
fragments (1099/+101, 307/+101, 15/+101, and +55/+101) of the APP gene, and a p53-expressing vector as indicated in the ﬁgure. CAT was determined after a 48-h
period of incubation in the presence or absence of 200 nM T3. Data are expressed as mean ± S.D. of CAT activities obtained from two independent experiments performed in
duplicate.
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down demonstrated that modulation of the APP response to UVC
by T3 also requires a functional p53. In the absence of p53, UV irra-
diation was unable to signiﬁcantly reduce APP levels, and T3 did
not reverse the residual decrease induced by UV, thus conﬁrming
that p53 mediates not only the inhibitory effect of the UV, but also
the T3-induced reversion of that reduction.On the other hand, although T3, as well as p53, can transcrip-
tionally inhibit APP expression, the reversion of p53-dependent
repression of APP by T3 does not appear to be directly mediated
by a transcriptional-dependent mechanism at the APP promoter le-
vel. The hormonal effect might be mediated by other mechanism/s
that could involve activation of cell signaling pathways that mod-
ulate the intracellular content of APP. Among others, the Ras/MAPK
2406 A. Cuesta et al. / FEBS Letters 583 (2009) 2401–2406or PI3K/Akt signaling pathways that stimulate APP promoter activ-
ity [34], can be activated by thyroid hormones through non-geno-
mic mechanisms [35,36], and may interact with p53 [37]. In
particular, the effects of T3 on p53-dependent APP repression could
have been mediated by cyclooxygenase-2 (Cox-2), a protein that is
increased in the brain of patients with Alzheimer’s disease and en-
hances the b-amyloid deposition through APP induction [38]. Of
interest, it has been previously reported in glioma cells [36], that
thyroid hormones may interfere with the nuclear interaction of
activated ERK1/2 and COX-2 protein, which is essential to activa-
tion of p53, and the subsequent p53-dependent apoptosis. How-
ever, COX-2 is not regulated by thyroid hormones in N2ab cells
or in the parental N2a cell line, which does not express the thyroid
hormone nuclear receptor. Furthermore, we have analyzed the ef-
fects of the thyroid hormones T3 and T4 on the UV-dependent de-
crease of APP, and have obtained data that appear to discard a non-
genomic effect mediated by a membrane receptor and COX-2.
Although new experiments should be performed to deﬁnitely
clarify the mechanisms that mediate the crosstalk between p53
and thyroid hormones, it is clear that it requires binding of the hor-
mone to the nuclear receptor, since it is not present in cells lacking
TRs, and that very likely involves the activation of signals thatmight
regulate APP expression and/or the enzymatic processing of this
protein. Moreover, according to the present results the thyroid hor-
mones could have a previously unrecognized role, protecting the
brain against p53-mediated neurodegeneration processes, and
therefore it would be essential to analyze the effect of p53 and thy-
roid hormone on APP in vivo, and also conﬁrmwhether thyroid hor-
mones can be actually useful in the prevention of this pathology.
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